Polypharmacy Increases Risk of Dyspnea Among Adults With Serious, Life-Limiting Diseases.

Kathleen M AkgünSupriya KrishnanShelli L FederJanet TateJean S KutnerKristina Crothers

Published in: The American journal of hospice & palliative care (2019)

Polypharmacy was strongly associated with dyspnea. Prospective interventions to decrease polypharmacy may impact dyspnea symptoms, especially for statins.

Keyphrases

adverse drug
advanced cancer
cardiovascular disease
palliative care
type diabetes
sleep quality
depressive symptoms